Triumvira Immunologics, Inc. ('Triumvira') is a clinical stage immunotherapy company with the vision of developing novel T-cell therapies that are safer and more efficacious than current cell therapy cancer treatments, including chimeric antigen receptor (CAR) and engineered T-cell receptor (TCR) therapies. Our proprietary T-cell Antigen Coupler (TAC) technology recruits the entire natural T-cell receptor and functions independent of the Major Histocompatibility Complex (MHC), potentially allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and with diseases other than cancer.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/27/20 | $55,000,000 | Series A |
Bloom Burton & Co Centre for Commercialization of Cancer Immunotherapy Leaps by Bayer  Northpond Ventures Oceanpine Capital Viva Biotech | undisclosed |
| 03/17/22 | $100,000,000 | Series A Extension |
ATEM Capital B Capital Group Leaps by Bayer Myeloma Investment Fund Northpond Ventures | undisclosed |
